Payment overview · 2025
General Payments
$567.21
35 reported records · 15 companies
Healthcare provider profile · identity verified
Joe Benjamin Proctor, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW IBERIA, LA · NPI 1205129582
Verified facts
What the public records show
CMS Open Payments records show Joe Benjamin Proctor, M.D. received $567.21 in general payments during 2025 across 35 reported records.
Amgen Inc. accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $135.37 | 23.9% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $80.62 | 14.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.84 | 8.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.96 | 7.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.69 | 7.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $35.74 | 6.3% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $28.71 | 5.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.46 | 4.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.32 | 3.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.08 | 3.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.39 | 3.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.20 | 3.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.21 | 2.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $15.95 | 2.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.67 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $567.21 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $104.61 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $90.94 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $65.89 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $45.78 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.96 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.69 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $35.74 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.76 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $28.71 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 161 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 135 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 227 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 188 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
135 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
227 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
90 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
227 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
188 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
161 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 715 | 158 |
| Atorvastatin Calcium | Atorvastatin Calcium | 685 | 182 |
| Pantoprazole Sodium | Pantoprazole Sodium | 383 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 352 | 69 |
| Gabapentin | Gabapentin | 298 | 73 |
| Metformin Hcl | Metformin Hcl | 298 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 273 | 60 |
| Trazodone Hcl | Trazodone Hcl | 253 | 43 |
| Meloxicam | Meloxicam | 246 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 244 | 60 |
| Jardiance | Empagliflozin | 227 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 212 | 41 |
| Sertraline Hcl | Sertraline Hcl | 200 | 31 |
| Lisinopril | Lisinopril | 197 | 46 |
| Losartan Potassium | Losartan Potassium | 194 | 41 |
| Mounjaro | Tirzepatide | 188 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 56 |
| Montelukast Sodium | Montelukast Sodium | 187 | 35 |
| Eliquis | Apixaban | 161 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 159 | 62 |
| Paroxetine Hcl | Paroxetine Hcl | 157 | 25 |
| Alendronate Sodium | Alendronate Sodium | 153 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 140 | 22 |
| Farxiga | Dapagliflozin Propanediol | 135 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 34 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 127 | 26 |
| Donepezil Hcl | Donepezil Hcl | 126 | 21 |
| Prednisone | Prednisone | 125 | 85 |
| Glipizide | Glipizide | 124 | 25 |
| Valsartan | Valsartan | 120 | 30 |
| Omeprazole | Omeprazole | 118 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 32 |
| Ezetimibe | Ezetimibe | 117 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 32 |
| Cefdinir | Cefdinir | 115 | 87 |
| Famotidine | Famotidine | 114 | 27 |
| Atenolol | Atenolol | 112 | 25 |
| Simvastatin | Simvastatin | 109 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 102 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 91 | 19 |
| Potassium Chloride | Potassium Chloride | 91 | 42 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 91 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 11 |
| Allopurinol | Allopurinol | 84 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 22 |
| Pregabalin | Pregabalin | 79 | 14 |
| Carvedilol | Carvedilol | 75 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 21 |
| Furosemide | Furosemide | 73 | 15 |
| Januvia | Sitagliptin Phosphate | 73 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 12 |
| Doxepin Hcl | Doxepin Hcl | 71 | 17 |
| Glimepiride | Glimepiride | 71 | 16 |
| Spironolactone | Spironolactone | 71 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 69 | suppressed |
| Trulicity | Dulaglutide | 66 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 63 | 12 |
| Linzess | Linaclotide | 63 | 14 |
| Entresto | Sacubitril/Valsartan | 61 | suppressed |
| Irbesartan | Irbesartan | 58 | suppressed |
| Glipizide Er | Glipizide | 57 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 56 | suppressed |
| Ozempic | Semaglutide | 53 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 50 | suppressed |
| Repatha Sureclick | Evolocumab | 48 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 48 | 11 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Clonazepam | Clonazepam | 46 | suppressed |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | suppressed |
| Alprazolam | Alprazolam | 43 | suppressed |
| Levofloxacin | Levofloxacin | 43 | 31 |
| Azithromycin | Azithromycin | 42 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 35 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 38 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 37 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 37 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | 11 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 12 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 19 |
| Mupirocin | Mupirocin | 24 | 21 |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Cimetidine | Cimetidine | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Praluent Pen | Alirocumab | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Meropenem | Meropenem | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 14 |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Zypitamag | Pitavastatin Magnesium | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 11 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $567.21 · 35 records | Amgen Inc. | AIRSUPRA, Azstarys, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, IBSRELA, JARDIANCE, Kerendia, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, REPATHA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, VRAYLAR | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error